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ABSTRACT Objectives. To compare national essential medicines lists (NEMLs) from countries in the Region of the Americas 
and to identify potential opportunities for improving those lists.
 Methods. In June of 2017, NEMLs from 31 countries in the Americas were abstracted from documents included 
in a World Health Organization (WHO) repository. The lists from the Americas were compared to each other 
and to NEMLs from outside of the Americas, as well as with the WHO Model List of Essential Medicines, 20th 
edition (“WHO Model List”) and the list of the Pan American Health Organization (PAHO) Regional Revolving 
Fund for Strategic Public Health Supplies (“Strategic Fund”).
 Results. The number of differences between the NEMLs from the Americas and the WHO Model List were 
similar within those countries (median: 295; interquartile range (IQR): 265 to 347). The NEMLs from the Ameri-
cas were generally similar to each other. While the NEMLs from the Americas coincided well with the Strategic 
Fund list, some medicines were not included on any of those NEMLs. All the NEMLs in the Americas included 
some medicines that were withdrawn due to adverse effects by a national regulatory body (median: 8 with-
drawn medicines per NEML; IQR: 4 to 12).
 Conclusions. The NEMLs in the Americas were fairly similar to each other and to the WHO Model List and the 
Strategic Fund list. However, some areas of treatment and some specific medicines were identified that the 
countries should reassess when revising their NEMLs.
Keywords Formulary; Americas; access to essential medicines and health technologies; World Health Organization; Pan 
American Health Organization.
Essential medicines lists are meant to promote equity in 
health by ensuring that quality medicines are available and 
accessible in a functioning health system, in appropriate forms, 
at affordable prices, and distributed in an equitable fashion (1). 
The World Health Organization (WHO) Model List of Essential 
Medicines (“WHO Model List”) (2) is revised biannually (3). 
The WHO Model List serves as a guide for countries’ national 
essential medicines lists (NEMLs), which prioritize a core set of 
medicines based on each country’s health needs (1, 4). NEMLs 
are used to guide medicine selection, appropriate use, medicine 
reimbursement, and medicine procurement, and they should be 
regularly updated (5, 6).
NEMLs guide medicine access for over 600 million people 
in the Region of the Americas (7). All countries with an NEML 
in the Americas are Member States of the Pan American 
Health Organization (PAHO), which works with countries to 
improve and protect the health of the people in their nation or 
territory (8).
In total, PAHO consists of 49 countries and territories (35 
Member States plus 14 others categorized as participating, 
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associate, or observer states) (9). PAHO promotes evidence-based 
choices for the countries’ NEML medicine selection through its 
Regional Revolving Fund for Strategic Public Health Supplies 
(the “Strategic Fund”) (10). The Strategic Fund has created 
its own list of medicines, based on the WHO Model List (11), 
that are available for procurement on behalf of PAHO Member 
States to leverage economies of scale in order to assist countries 
in the acquisition of quality, safe and effective medicines and 
other health supplies and services at affordable prices (12). The 
Strategic Fund also aims to build capacity at the national level 
for drug supply management and procurement programming 
and planning (12).
To our knowledge, no studies have compared NEMLs across 
countries in the Americas. This study sought to compare avail-
able NEMLs in the Americas with the WHO Model List (20th 
edition, 2017) to determine potential recommendations for 
NEMLs in the Americas.
METHODS
Creation of the database
In June of 2017 we searched the WHO Essential Medicines 
and Health Products Information Portal, an online repository 
that contains hundreds of publications on medicines and health 
products related to WHO priorities (13, 14). We included all 
NEMLs that were posted on that repository, irrespective of their 
publication date and language. When more than one NEML 
was found for a country, the most recent was used. Detailed 
explanation of these methods is described elsewhere (15). The 
original database was updated with an NEML from Panama, 
and with other minor corrections.
Exclusion criteria
We excluded documents that were not NEMLs, such as pre-
scribing guidelines, and some medicines, including diagnostic 
agents, antiseptics, disinfectants, and saline solutions.
Data extraction
From each country’s NEML, medicines were abstracted 
using International Nonproprietary Names (16). For medicines 
whose names were not in English we used the Anatomical 
Therapeutic Chemical (ATC) classification system, if available, 
or translated the names with the help of the Google Translate 
website (17, 18). Each medicine was listed individually, whether 
it was part of a combination product or not. Medicine bases and 
their salts were combined (e.g., promethazine hydrochloride 
and promethazine), as well as different compounds of the same 
vitamin or mineral (e.g., ferrous fumarate and ferrous sulfate). 
Detailed methods for the creation of the database, including 
data extraction, are described elsewhere (15).
Data analysis
We determined the number of differences between each 
country’s NEML and the WHO Model List (20th edition, 2017), 
including both the number of medicines on the WHO Model 
List but not on the respective NEML and the number of medi-
cines on the respective NEML but not on the WHO Model List. 
Also for the countries in the Americas we determined the num-
ber of medicines that were on each NEML and on the PAHO 
Strategic Fund list, and the number of medicines that were not 
on each NEML but were on the Strategic Fund list.
Similarity scores were calculated for the 31 countries in the 
Americas by dividing medicines into two groups, those that 
were commonly listed (≥ 50%) and those that were uncommonly 
listed (< 50%). For each country’s NEML, a similarity score was 
calculated by totaling commonly listed medicines and uncom-
monly listed medicines, and then subtracting uncommonly 
listed from commonly listed medicines. Higher numbers indi-
cate more similarity and lower scores indicate less similarity, in 
comparison to other NEMLs in the Americas.
Withdrawn medicines on NEMLs were identified in a pre-
vious study (19). We determined which ones were present on 
NEMLs in the Americas and calculated the number present on 
each country’s NEML.
RESULTS
We included NEMLs from 138 countries: 31 in the Ameri-
cas (89% of the 35 PAHO Member States) and 107 outside of 
the Americas (15). PAHO Member States that did not have an 
NEML in the online WHO NEMLs repository were the Baha-
mas, Canada, Guatemala, and the United States of America. 
The publication years for the NEMLs in the Americas ranged 
from 2004 to 2017.
The number of medicines on the individual lists from the 
Americas lists ranged from 197 to 704 (median: 361; interquar-
tile range (IQR): 290 to 456) (Table 1). In comparison, the values 
for other world regions were: Africa, 64 to 702 (median: 298; 
IQR: 248 to 347); Eastern Mediterranean, 200 to 964 (median: 
462; IQR: 278 to 623); Europe, 181 to 980 (median: 398; IQR: 
285 to 601); Southeast Asia, 44 to 546 (median: 291; IQR: 230 to 
343); and Western Pacific, 177 to 742 (median: 249; IQR: 215 to 
295) (15).
In total, the 138 NEMLs contained 2 081 unique medicines. 
We identified 1 264 medicines included on the lists of the Amer-
icas, of which more than two-fifths (541; 43%) were listed by 3 
or fewer countries.
Comparison with the WHO Model List
We determined the number of differences between each 
country’s NEML and the WHO Model List, including both the 
number of medicines on the WHO Model List but not on the 
NEML and the number of medicines on the NEML but not on 
the WHO Model List (15). At the time of our study, the WHO 
Model List had 415 medicines on it. The number of differences 
between NEMLs in the Americas and the WHO Model List 
ranged from 175 to 531 (median: 295; IQR: 265 to 347) (Table 1). 
The values for the other world regions were: Africa, 208 to 538 
(median: 281; IQR: 267 to 323); Eastern Mediterranean, 93 to 753 
(median: 352; IQR: 249 to 502); Europe, 211 to 813 (median: 415; 
IQR: 337 to 535); Southeast Asia, 231 to 463 (median: 273; IQR: 
243 to 329); and Western Pacific, 239 to 595 (median: 307; IQR: 
284 to 347) (15).
In the Americas, 23 medicines from the WHO Model List 
were not included on any NEML (Table 2) (15). The Domini-
can Republic, Mexico, and Peru included more than 290 (70%) 
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Antigua and Barbuda ATG 1 105 2007 292 291 207 84 90 90 204
Argentina ARG 1 390 2011 469 312 129 183 126 54 113
Barbados BRB 1 234 2011 624 507 149 358 118 62 −60
Belize BLZ 524 2008 370 279 162 117 110 70 134
Bolivia (Plurinational 
State of)
BOL 446 2011 353 270 166 104 124 56 169
Brazil BRA 1 392 2014 406 347 178 169 117 63 12
Chile CHL 1 903 2005 349 314 190 124 110 70 153
Colombia COL 853 2011 371 288 166 122 120 60 125
Costa Rica CRI 1 287 2014 389 354 190 164 108 72 85
Cuba CUB 2 479 2012 505 358 134 224 133 47 45
Dominica DMA 586 2007 284 295 213 82 89 91 202
Dominican Republic DOM 873 2015 356 175 117 58 136 44 172
Ecuador ECU 980 2013 370 243 144 99 133 47 118
El Salvador SLV 579 2009 361 268 161 107 116 64 157
Grenada GRD 678 2007 282 303 218 85 85 95 196
Guyana GUY 336 2010 280 265 200 65 96 84 156
Haiti HTI 120 2012 197 248 233 15 88 92 155
Honduras HND 353 2009 366 325 187 138 106 74 112
Jamaica JAM 511 2012 456 343 151 192 122 58 104
Mexico MEX 1 009 2011 704 531 121 410 133 47 −162
Nicaragua NIC 406 2011 272 261 202 59 106 74 180
Panama PAN 1 543 2017 601 398 106 292 143 37 −65
Paraguay PRY 724 2009 307 272 190 82 114 66 161
Peru PER 671 2012 424 243 117 126 140 40 138
Saint Kitts and Nevis KNA 1 443 2007 290 297 211 86 89 91 206
Saint Lucia LCA 681 2007 290 297 211 86 89 91 206
Saint Vincent and the 
Grenadines
VCT 470 2010 267 250 199 51 100 80 201
Suriname SUR 1 017 2014 285 260 195 65 103 77 151
Trinidad and Tobago TTO 2 204 2010 492 377 150 227 122 58 58
Uruguay URY 1 748 2011 518 445 171 274 109 71 −14
Venezuela (Bolivarian 
Republic of)
VEN 579 2004 306 289 199 90 116 64 160
Table 1 notes: ISO-3: International Organization for Standardization alpha-3 letter codes; $Intl: International dollars; NEML: national essential medicines list; Strategic Fund List (refers to the Pan American Health Organization - Regional 
Revolving Fund for Strategic Public Health Supplies); WHO: World Health Organization.
Source: Authors’ results and data from publicly available sources as summarized below:
a We obtained the countries’ alpha three-letter codes from the International Organization for Standardization (ISO) 3166-1, Online Browsing Platform.
b Health care expenditure per capital from the WHO/Global Health Observatory data repository.
these NEMLs, the Dominican Republic and Peru listed med-
icines from the WHO Model List without adding many other 
medicines (fewer than 130), while Mexico added over 400 medi-
cines to its list that were not on the WHO Model List. Dominica, 
Grenada, Haiti, Saint Kitts and Nevis, and Saint Lucia omitted 
over 207 (50%) of the medicines on the WHO Model List from 
their NEMLs (Table 1).
For neglected tropical diseases, there were two medicines 
(benznidazole and nifurtimox) for American trypanosomiasis 
(Chagas disease) and five antileishmaniasis medicines (ampho-
tericin B, miltefosine, paromomycin, meglumine, and 
stibogluconate) on the WHO Model List. Ten countries in 
the Americas listed at least one medicine to treat Chagas dis-
ease, while 30 countries listed at least one medicine to treat 
leishmaniasis. Haiti was the only country that did not list any 
treatment for either disease.
Countries in the Americas with lower health care expendi-
tures appear to have omitted more WHO essential medicines 
from their lists (e.g., Haiti and Nicaragua), and countries with 
higher health care expenditures appear to have included more 
medicines on their lists that are not on the WHO Model List 
(e.g., Barbados, Mexico, Panama, and Uruguay), although there 
are exceptions (e.g., Antigua and Barbuda) (Figure 1).
Comparison with the Strategic Fund list
The Strategic Fund list includes 180 unique medicines; 95% 
of listed medicines are also included on the WHO Model List. 
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The number of medicines listed on both the Strategic Fund list 
and a specific country’s NEML ranged from 85 to 143 (median: 
114; IQR: 100 to 124) (Table 1). Six countries (Cuba, Dominican 
Republic, Ecuador, Mexico, Panama, and Peru) included more 
than 126 (70%) of the Strategic Fund medicines on their respect-
ive NEML.
The number of medicines listed on the Strategic Fund list and 
not on a specific country’s NEML ranged from 37 to 95 (median: 
66; IQR: 56 to 80) (Table 1). We identified 9 medicines that are 
listed on both the Strategic Fund list and the WHO Model List 
but not by any country in the Americas (Table 2); these med-
icines are commonly used in the treatment of hepatitis C, 
tuberculosis, human immunodeficiency virus, and malaria. 
Atovaquone (ATC: P01AX06), which is used in the treatment of 
malaria, pneumocystis pneumonia, and toxoplasmosis, is not 
on the WHO Model List or any NEML in the Americas but is 
included on the Strategic Fund list.
Velpatasvir, a medicine used in combination for treatment of 
hepatitis C, was not listed by any NEML in the Americas. Seven 
other medicines for hepatitis C (daclatasvir, dasabuvir, ledipas-
vir, ombitasvir, paritaprevir, sofosbuvir, and simeprevir) were 
each listed by fewer than three countries. All of these medicines 
for hepatitis C treatment are included on the Strategic Fund list. 
The other medicines included on the WHO Model List for the 
treatment of hepatitis C are ribavirin and pegylated interferon 
alfa, which are used in combination; only six countries in the 
Americas (Brazil, Cuba, Honduras, Mexico, Panama, and Uru-
guay) listed these medicines.
Four antituberculosis medicines rifapentine (treatment of 
latent tuberculosis infections) and bedaquiline, delamanid, and 
protionamide (part of treatment regimens for multidrug and 
































































On national list, but not on WHO Model List
WHO: World Health Organization (Model List of Essential Medicines, 20th edition, 2017).
The width of the circles represents the country’s health expenditure. We obtained the countries’ three-letter codes from the International Organization for Standardization (ISO) 3166-1 Online Browsing Platform; ATG: 
Antigua and Barbuda; ARG: Argentina; BRB: Barbados; BLZ: Belize; BOL: Bolivia (Plurinational State of); BRA: Brazil; CHL: Chile; COL: Colombia; CRI: Costa Rica; CUB: Cuba; DMA: Dominica; DOM: Dominican 
Republic; ECU: Ecuador; SLV: El Salvador; GRD: Grenada; GUY: Guyana; HTI: Haiti; HND: Honduras; JAM: Jamaica; MEX: Mexico; NIC: Nicaragua; PAN: Panama; PER: Peru; PRY: Paraguay; KNA: Saint Kitts and 
Nevis; LCA: Saint Lucia; VCT: Saint Vincent and the Grenadines; SUR: Suriname; TTO: Trinidad and Tobago; URY: Uruguay; VEN: Venezuela (Bolivarian Republic of).
Source: Authors’ results.
TABLE 2. Medicines listed by the WHO Model List but not 
included on any national essential medicines list in the Region 
of the Americas














Etonogestrel-releasing implant (G03AC08) No
Faropenem (J01DI03) No
Japanese encephalitis vaccine (J07BA02) No
Melarsoprol (P01CD01) No




Tick-borne encephalitis immunoglobulin (J06BB12) No
Ulipristal (G03AD02) No
ATC: Anatomical Therapeutic Chemical classification system. WHO Model List refers to the World Health Organization’s 
Model List of Essential Medicines, 20th version (2017); Strategic Fund listed indicates that the medicines are included 
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extensively drug-resistant tuberculosis)) are not listed on any 
NEML in the Americas. These medicines are included on the 
WHO Model List and the Strategic Fund list.
Between-country comparisons
The similarity scores for the Americas, measuring the extent 
to which countries tend to list medicines commonly listed 
by other countries in the Americas, ranged from −162 to 206 
(median: 151; IQR: 85 to 172) (Table 1). Most countries in the 
Americas had a positive similarity score, indicating that most 
of the medicines listed by those countries were also listed by 
the majority of countries included in this analysis. Mexico had a 
large negative similarity score (−162), indicating that the major-
ity of medicines on its list were not listed by most countries in 
the Americas.
Discrepant medicines
We identified medicines that could be added or removed 
from NEMLs in the Americas by calculating whether medicines 
were commonly listed (listed by ≥ 50% of countries) in each 
WHO region. Medicines that are not commonly listed in the 
Americas but are on the WHO Model List and commonly listed 
by at least three other regions (50% of the WHO regions) could 
be considered for addition (Table 3). Medicines commonly 
listed within the Americas but not on the WHO Model List or 
not commonly listed by any other region could be considered 
for removal (Table 3).
Withdrawn medicines are those that have been withdrawn 
after market approval or those that were not approved by 
a national regulatory body because of adverse effects (19). 
Withdrawn medicines were present on all the NEMLs of the 
Americas; these ranged from 2 to 24 medicines (median: 8; 
IQR: 4 to 12) (Table 4). Of the 31 studied countries in the Amer-
icas, 10 of them (32%) listed 11 or more withdrawn medicines. 
Three internationally withdrawn medications were present on 
NEMLs in the Americas: drotrecogin alfa (Mexico); nikethamide 
(Cuba); and thioridazine, an antipsychotic that was withdrawn 
by the manufacturer (Novartis) in 2005 (19), (listed by 18 of the 
31 countries in the Americas (58%)).
DISCUSSION
We found that NEML listings across countries in the Ameri-
cas are similar to each other, with a few exceptions (including 
Barbados, Mexico, Panama, and Uruguay), and similar to the 
WHO Model List (Table 1). Some medicines listed by multi-
ple countries in the Americas could be considered for removal 
because they are not listed in either the WHO Model List or 
by many other countries (e.g., trifluoperazine) or because they 
have been withdrawn in other countries (e.g., thioridazine). 
Some medicines that are not listed by many countries in the 
Americas should be considered for addition, such as medicines 
on the Strategic Fund list (e.g., tuberculosis treatments).
The WHO states that medicine availability and price are key 
indicators of access to treatment (20). NEMLs are commonly 
used to guide public sector procurement (20), and they have 
been shown to be more available than other medicines, par-
ticularly in the public sector  (21). Therefore, the content of an 
NEML can affect health outcomes.
TABLE 3. Medicines that may be considered for addition or 
removal from national essential medicines lists in the Region 
of the Americas, with the medicines’ Anatomical Therapeutic 
































The WHO recommends that their Model List be used to 
guide countries to the best evidence-based medicines and not 
necessarily be replicated on NEMLs. Countries should select 
medicines based on their own, specific priority health care 
needs (20). Having a larger overlap of medicines with the WHO 
Model List may not guarantee better health outcomes for coun-
tries. Health care services and quality of care are also important 
factors that may affect health outcomes. The purpose of a 
comparison with the WHO Model List is to encourage coun-
tries to evaluate their list based on our findings to ensure that 
their NEMLs use the best evidence-based medicines to meet 
the needs of their country. We acknowledge that there are other 
factors, such as relationships with pharmaceutical manufactur-
ers and structural differences within health systems, that may 
influence NEML listing decisions.
List comparisons
Within the Americas, Mexico’s NEML was the least like 
those of other countries, as it was the longest (at 704 medicines) 
and it had the lowest similarity score. Countries may find that 
with a longer NEML it is harder to maintain an adequate and 
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TABLE 4. Withdrawn medicines included on national essential medicines lists in the Region of the Americas
Withdrawn medicine (ATC code) Safety concern Countries listing the medicine (no.)
Benzbromarone (M04AB03) Hepatic damage Panama (1)
Bismuth (A02BX05) Encephalopathy Argentina, Belize, Cuba, Jamaica, Mexico, Panama, Peru, Suriname, Trinidad and 
Tobago, Uruguay (10)
Carisoprodol (M03BA02) Abuse potential Guyana (1)
Chloral hydrate (N05CC01) Tumorigenicity Barbados, Belize, Chile, Costa Rica, Cuba, Ecuador, Honduras, Jamaica, Mexico, 
Panama (10)
Chlormadinone (G03DB06) Tumorigenicity Mexico (1)
Chloroform (N01AB02) Cardiotoxicity, tumorigenicity Trinidad and Tobago (1)
Cisapride (A03FA02) Cardiac arrhythmias Barbados, Mexico, Uruguay (3)
Clioquinol (D08AH30) Subacute myelo-optic neuropathy  
(SMON), neurotoxicity
Barbados, Mexico, Panama, Trinidad and Tobago (4)
Clobutinol (R05DB03) Long QT syndrome, cardiac arrhythmias Chile (1)
Clofibrate (C10AB01) Death, ventricular arrhythmias Barbados, Uruguay (2)
Diclofenac (M01AB05) Gastrointestinal, skin reactions Antigua and Barbuda, Argentina, Barbados, Belize, Bolivia, Chile, Colombia, Costa 
Rica, Cuba, Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, Guyana, 
Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Kitts 
and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and 
Tobago, Uruguay, Venezuela (Bolivarian Republic of) (30)
Dienestrol (G03CB01) Carcinogenicity Costa Rica (1)
Diethylstilbestrol/Stilboestrol (G03CB02) Tumorigenicity Argentina, Belize, Costa Rica, Cuba, Guyana, Jamaica, Panama, Peru (8)
Droperidol/Dehydrobenoperidol (N05AD08) Cardiotoxicity Argentina, Bolivia, Chile, Costa Rica, Cuba, Jamaica, Nicaragua (7)
Drotrecogin alfa (B01AD10)* Failure to show benefits Mexico (1)
Etretinate (D05BB01) Teratogenicity Trinidad and Tobago (1)
Fluvoxamine (N06AB08) Teratogenicity, nephrotoxicity Barbados, Panama, Trinidad and Tobago (3)
Furazolidone (G01AX06) Carcinogenic, skin Argentina, Colombia, Nicaragua, Peru (4)
Gatifloxacin (J01MA16) Dysglycemia Barbados (1)
Gemfibrozil (C10AB04) Adverse effects not balanced by benefits Argentina, Barbados, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, 
Nicaragua, Paraguay, Peru, Venezuela (Bolivarian Republic of) (13)
Kaolin (A07BC02) No evidence it works for its purpose Trinidad and Tobago (1)
Ketorolac (M01AB15) Gastrointestinal, skin reactions Barbados, Bolivia, Dominican Republic, Ecuador, El Salvador, Honduras, Mexico, 
Nicaragua, Paraguay, Trinidad and Tobago (10)
Lindane/ Gamma benzene hexachloride 
(P03AB02)
Potential toxicity Barbados, Belize, Guyana, Jamaica, Uruguay, Venezuela (Bolivarian Republic of) (6)
Meclizine (R06AE05) Teratogenic potential Cuba (1)
Megestrol (G03AC05) Tumorigenicity Argentina, Barbados, Honduras, Mexico, Panama, Uruguay (6)
Meprobamate (N05BC01) Abuse Cuba (1)
Metamizole/Dipyrone (N02BB02) Agranulocytosis Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Guyana, Honduras, Jamaica, 
Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay, Venezuela (Bolivarian Republic 
of) (17)
Metaproterenol/Orciprenaline (R03AB03) Cardiotoxicity Mexico (1)
Methylphenidate (N06BA04) Abuse Antigua and Barbuda, Argentina, Barbados, Belize, Bolivia, Chile, Colombia, Costa 
Rica, Cuba, Dominica, El Salvador, Grenada, Honduras, Jamaica, Mexico, Panama, 
Peru, Saint Kitts and Nevis, Saint Lucia, Suriname, Trinidad and Tobago, Uruguay, 
Venezuela (Bolivarian Republic of) (23)
Minocycline (A01AB23) Dizziness, vertigo Argentina, Barbados, Brazil, Cuba, Mexico (5)
Neomycin (A01AB08) Abuse Antigua and Barbuda, Argentina, Barbados, Belize, Bolivia, Chile, Colombia, Costa 
Rica, Cuba, Dominica, El Salvador, Grenada, Guyana, Jamaica, Mexico, Saint Kitts and 
Nevis, Saint Lucia, Suriname, Trinidad and Tobago, Uruguay (20)
Nikethamide (R07AB02)* Neurotoxicity Cuba (1)
Nimesulide (M01AX17) Hepatotoxicity Venezuela (Bolivarian Republic of) (1)
Phenazopyridine (G04BX06) Carcinogenicity Barbados, Costa Rica, El Salvador, Jamaica, Mexico, Uruguay (6)
Phentolamine (C04AB01) Carcinogenicity Argentina, Colombia, Cuba, Trinidad and Tobago, Venezuela (Bolivarian Republic 
of) (5)
Phenylpropanolamine (R01BA01) Hemorrhagic stroke Mexico (1)
Phthalylsulfathiazole (A07AB02) Granulocytopenia Uruguay (1)
Pioglitazone (A10BG03) Risk of bladder cancer Barbados, Jamaica, Mexico, Uruguay (4)
Pseudoephedrine (R01BA02) Neurotoxicity, gastrointestinal Barbados, El Salvador, Jamaica (3)
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consistent supply of medicines, therefore the WHO recom-
mends that countries list a limited number of carefully selected 
medicines (20). The reasons for Mexico’s longer list are not 
clear; Mexico is not the wealthiest country in the Americas, nor 
does it have the largest population (7). Policy process or polit-
ical factors, such as limited use of evidence-based processes in 
selecting medicines, as has been demonstrated in other settings, 
may explain observed differences among NEMLs (22).
There is fair overlap between medicines on the NEMLs and 
those with a negotiated price through the Strategic Fund list. 
This suggests that the Strategic Fund list may be influential in 
its intended goal of helping countries to improve access to some 
medicines. At the same time, some high-priced medicines on 
the Strategic Fund list are not on most of the NEMLs, includ-
ing treatments for hepatitis C, human immunodeficiency virus, 
tuberculosis, and malaria. This suggests that further work may 
be needed to make these medicines affordable, and perhaps 
price concerns have held up their listings on NEMLs.
We found that hepatitis C medicine listings on NEMLs are 
lacking in the Americas, with only 5 of 31 countries in the Amer-
icas (16%) having at least one treatment for it. That is despite the 
fact that the Strategic Fund list includes medicines for treating 
hepatitis C. Due to medical advances, 95% of people infected 
with hepatitis C could be cured. However, across the Ameri-
cas, the vast majority of infected people do not have affordable 
access to these highly effective medicines (23).
Mifepristone, which is used in emergency contraception and 
in therapeutic abortions, is included on the Strategic Fund list 
and on the WHO Model List (since 2006) with the note “where 
permitted under national law and where culturally acceptable”; 
it is not included by any country in the Americas.
Antituberculosis medicines like protionamide have been 
listed on the WHO Model List for decades. In addition, in 
April 2015, rifapentine (for latent tuberculosis infections) and 
bedaquiline and delamanid (latest second-line treatment for 
Withdrawn medicine (ATC code) Safety concern Countries listing the medicine (no.)
Rosiglitazone (A10BG02) Cardiotoxicity Barbados, Honduras, Mexico, Paraguay, Trinidad and Tobago (5)
Sulfacetamide (S01AB04) Eye, skin reactions Colombia, Cuba, Haiti, Jamaica, Mexico, Nicaragua, Peru (7)
Sulfathiazole (J01EB07) Nephrotoxicity, hepatotoxicity, skin 
reactions
Cuba (1)
Tegaserod maleate (A06AX06) Increased risk of heart attacks and  
strokes
Mexico (1)
Thalidomide (L04AX02) Teratogenicity Argentina, Barbados, Bolivia, Brazil, Colombia, Costa Rica, Cuba, Ecuador, El 
Salvador, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Suriname,  
Uruguay (17)
Thioridazine (N05AC02)* Cardiac arrhythmias, QT prolongation Antigua and Barbuda, Barbados, Belize, Bolivia, Chile, Colombia, Cuba, Dominica, 
Grenada, Guyana, Nicaragua, Peru, Saint Kitts and Nevis, Saint Lucia, Saint Vincent 
and the Grenadines, Trinidad and Tobago, Uruguay, Venezuela (Bolivarian Republic 
of) (18)
Tolcapone (N04BX01) Hepatotoxicity Brazil (1)
Tranylcypromine (N06AF04) Drug-drug interactions Argentina (1)
Trazodone (N06AX05) Carcinogenicity Colombia (1)
Triazolam (N05CD05) Psychiatric adverse effects Mexico (1)
Valdecoxib (M01AH03) Cardiotoxicity, skin reactions Panama (1)
Vigabatrin (N03AG04) Neurotoxicity Brazil, Costa Rica, Cuba, Mexico (4)
Zopiclone (N05CF01) Carcinogenicity Barbados (1)
ATC: Anatomical Therapeutic Chemical classification system.
*Medicine has been withdrawn worldwide.
Source: Data retrieved from Charles et al. (19); data available from the corresponding author of this study.
TABLE 4. Withdrawn medicines included on national essential medicines lists in the Region of the Americas (continued)
multidrug-resistant infection) were added to the WHO Model 
List (24); as such, only NEMLs published after 2015 may have 
included these medicines.
The Dominican Republic and Panama were the only countries 
in the Americas that had an NEML published in 2015 or later, 
as of the time that we captured our study data. Ultimately, the 
choice of medicines included on NEMLs resides with national 
policymakers, and it is the responsibility of countries to regu-
larly update and publish their NEMLs.
Along with the medications identified for addition, when 
comparing NEMLs to the WHO Model List and the Strategic 
Fund list, other medicines were identified that countries could 
consider adding to their NEMLs (Table 3). If many regions 
outside of the Americas are commonly listing particular med-
icines (e.g., cefixime and ephedrine), there is a consensus that 
they are essential among those countries. Therefore, medicines 
that were commonly listed on NEMLs in other regions could be 
considered for addition to NEMLs in the Americas, keeping in 
mind each country’s epidemiological needs.
NEML medicine removals
We assessed medicines that countries could consider remov-
ing from their NEMLs (Table 3). If many countries outside of 
the Americas are not commonly listing particular medicines 
(e.g., labetalol), there may be a consensus among those coun-
tries that they are not essential. Several medicines on NEMLs in 
the Americas were identified as not approved or as withdrawn 
from the market due to adverse effects of the medicine (e.g., 
chloral hydrate and thioridazine) (Table 4). NEMLs are meant 
to guide medicine prescribing (5, 6), and it is important that 
they be reviewed regularly and that medicines with question-
able evidence be carefully considered for omission from the 
lists. In this way, known harms to the population that a list 
serves can be prevented.
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Treatments for priority noncommunicable disease interven-
tions identified in three WHO guidelines—Best Buys (25), PEN 
(26), and HEARTs technical package (5)—were present in most 
countries in the Americas, according to previous studies. Areas 
identified for improvement were influenza vaccination, human 
papillomavirus vaccine, and senna (sennosides) (27).
Strengths and limitations
This is the first and largest study comparing the medicines 
included in 31 NEMLs in the Region of the Americas. The size 
of the study offers some robustness to the findings, particularly 
our suggestions for NEML revisions in the Americas.
Our study has limitations. The database of NEMLs and 
medicines may not reflect current NEML listings, given that 
documents available from the WHO’s NEML repository were 
abstracted in 2017. In addition, some NEMLs required transla-
tion, standardized medicine nomenclature was not consistently 
used on some lists, and judgments had to be made about what 
to include in ambiguous cases. These issues made the process 
liable to errors. This quantitative analysis does not account for 
other contextual factors that could explain differences in which 
medicines are included on each NEML, such as local disease 
prevalence or national priorities.
Conclusions
Countries in the Americas have NEMLs that are similar and 
that have significant overlap with both the WHO and Strategic 
Fund lists. However, countries in the Americas were lacking 
NEML coverage of medicines for treatment of hepatitis C, 
human immunodeficiency virus, tuberculosis, and malaria. 
Regularly updating NEMLs (as recommended by the WHO) 
and purchasing medicines through the Strategic Fund may 
help improve access to essential medicines and universal health 
coverage in the Americas. This may lead to improvements in 
measurable health outcomes and ultimately better the health of 
people in the Americas.
Recommendations
When updating their NEMLs, studied countries in the Amer-
icas should consider the differences between their respective 
NEML and the WHO Model List and the other NEMLs in the 
Americas. Countries should also assess adding or removing 
medications from their NEML based on listings in other WHO 
regions, and they should also weigh removing medications that 
were withdrawn, particularly ones that have been withdrawn 
worldwide.
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Comparación de las listas nacionales de medicamentos esenciales en las 
Américas
RESUMEN Objetivos.  Comparar las listas nacionales de medicamentos esenciales (LNME) de países de la Región de 
las Américas e identificar oportunidades potenciales de mejorarlas.
 Métodos. En junio de 2017, se extrajeron las LNME de 31 países de la Región de documentos incluidos en 
un repositorio de la Organización Mundial de la Salud (OMS). Se compararon estas listas entre sí y con listas 
de fuera de la Región, así como con la Lista Modelo de Medicamentos Esenciales de la OMS (20ª edición) 
y la lista del Fondo Rotatorio Regional para Suministros Estratégicos de Salud Pública de la Organización 
Panamericana de la Salud.
 Resultados. El número de diferencias entre las LNME de la Región y la Lista Modelo de la OMS fue similar 
dentro de esos países (mediana: 295; rango intercuartil (RIC): 265 a 347). Las LNME de la Región en general 
fueron similares entre sí. Si bien las LNME de la Región mostraron una coincidencia adecuada con la lista del 
Fondo Rotatorio, algunos medicamentos no estaban incluidos en ninguna de las primeras. Todas las LNME de 
la Región incluían algunos medicamentos que habían sido retirados del mercado por las autoridades regula-
torias nacionales debido a efectos adversos (mediana: 8 medicamentos retirados en cada lista; RIC: 4 a 12).
 Conclusiones. Las LNME en la Región de las Américas son bastante similares entre sí y con la Lista Modelo 
de la OMS y la lista del Fondo Rotatorio de la OPS. Sin embargo, se identificaron algunas áreas terapéuticas 
y algunos medicamentos específicos que los países deberían reevaluar al revisar sus LNME.
Palabras clave Formulario farmacéutico; Américas; acceso a medicamentos esenciales y tecnologías sanitarias; Organi-
zación Mundial de la Salud; Organización Panamericana de la Salud
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Comparação entre listas nacionais de medicamentos essenciais nas 
Américas
RESUMO Objetivos.  Comparar as listas nacionais de medicamentos essenciais (LNME) dos países da Região das 
Américas e identificar oportunidades potenciais de melhoria.
 Métodos. Em junho de 2017, as LNME de 31 países das Américas foram obtidas de documentos incluídos 
em um repositório da Organização Mundial da Saúde (OMS). As listas foram comparadas entre si, com listas 
de fora da Região, com a Lista Modelo de Medicamentos Essenciais da OMS (20ª edição) e com a lista do 
Fundo Rotativo Regional para Fornecimentos Estratégicos de Saúde Pública da Organização Pan-Americana 
da Saúde (Fundo Estratégico).
 Resultados. As LNME dos países das Américas eram semelhantes entre si e apresentaram um número 
semelhante de diferenças em relação à Lista Modelo da OMS (mediana: 295; intervalo interquartil: 265-347). 
Embora as LNME nas Américas fossem altamente consistentes com a lista do Fundo Estratégico, alguns dos 
medicamentos do Fundo não apareciam em nenhuma dessas LNME. Todas as LNME nas Américas incluíam 
medicamentos retirados do mercado por algum organismo regulador nacional devido a efeitos adversos 
(mediana: 8 medicamentos retirados por LNME; intervalo interquartil: 4-12).
 Conclusões. As LNME nas Américas são bastante semelhantes entre si e próximas da Lista Modelo da OMS 
e da lista do Fundo Estratégico. Contudo, foram identificadas algumas áreas terapêuticas e alguns medica-
mentos específicos que os países deveriam reavaliar ao rever as suas LNME.
Palavras-chave Formulário farmacêutico; Américas; acesso a medicamentos essenciais e tecnologias em saúde; Organi-
zação Mundial da Saúde; Organização Pan-Americana da Saúde
